learningcurve2020,
FDA will almost never peek until there is no more plausible explanation. The DMC may have recommended a halt but until a median can be established for actual benefit, the company has a right to keep everything continuing to insure best benefit outcome. FDA can change things up, though, if they have reason to believe some group is being placed in a less advantaged situation and median will be reached without adding any more to this group than necessary to preserve the integrity of the trial. Best wishes.
Market Data 
Markets 
AI
